Finasteride Tablet, Film Coated
Product Images NDC 50090-6941

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Finasteride (NDC 50090-6941). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 Symptom Score In A Long-term Efficacy And Safety Study (Finasteride Fig1)

Line graph titled 'Symptom Score in a Long-Term Efficacy and Safety Study' showing mean change from baseline with ±1 SE over four years. Two groups are compared: Finasteride and Placebo. The graph indicates mean symptom scores decreasing more with Finasteride than with Placebo during the study period.*

FDA Label Image

Figure 2 Percent Of Patients Having Surgery For Bph, Including Turp (Finasteride Fig2)

A line graph titled 'Percent of Patients Having Surgery for BPH, Including TURP' showing cumulative percentage of patients over 48 months. The chart compares Finasteride (solid line) and Placebo (dashed line) groups, indicating lower percent surgery rates for Finasteride. Below the graph are tables listing cumulative number of events and patients at risk per year for each group.*

FDA Label Image

Figure3 (Finasteride Fig3)

A line graph titled 'Percent of Patients Developing Acute Urinary Retention (Spontaneous and Precipitated)' comparing Finasteride and Placebo groups over 48 months. The y-axis shows percent of patients (0% to 15%), and the x-axis shows observation time in months (0 to 48). Two lines represent Finasteride (solid) and Placebo (dashed), showing lower incidence with Finasteride. The chart includes cumulative event counts and patients at risk per year for both groups.*

FDA Label Image

Figure4 (Finasteride Fig4)

A line graph titled 'Prostate Volume in a Long-Term Efficacy and Safety Study' depicting mean percent change from baseline in prostate volume over four years. The x-axis shows time points from baseline to year 4, and the y-axis shows mean percent change ranging from -20 to 20. Two lines represent placebo (circle markers) showing an increase in prostate volume, and finasteride (square markers) showing a decrease and stabilization of prostate volume. Sample sizes for each group at each time point are listed below the graph.*

FDA Label Image

Figure5 (Finasteride Fig5)

A line graph titled 'Cumulative Incidence of a 4-Point Rise in AUA Symptom Score by Treatment Group' depicting the percentage with event over years from randomization. Four treatment groups are shown: Placebo, Finasteride, Doxazosin, and Combination, illustrating their incidence trends over 5.5 years.*

FDA Label Image

Chemical Structure (Finasteride Str)

Chemical structure of finasteride, depicting its steroidal backbone with attached functional groups including a lactam ring and various methyl substituents.*

FDA Label Image

Label Image (Lbl500906941)

Finasteride 5 mg film-coated tablets label shows the product name, strength, and dosage form. The label lists the active ingredient as finasteride 5 mg per tablet, includes storage instructions (store at 68 to 77 degrees Fahrenheit, protect from light), and notes the quantity as 90 tablets. The labeler is A-S Medication Solutions in Libertyville, Illinois, with product NDC 50090-6941.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.